retatrutide mechanism glp-1 gip glucagon triple agonist Retatrutide—A Game Changer in Obesity Pharmacotherapy Retatrutide: The triple agonist powering

In particular, the first study demonstrated that, along with improvements in anthropometric parameters, HOMA-IR reduced in both treatment arms, but liraglutide 1.2 mg/day was superior to metformin also in reducing glucose levels at 120 min during OGTT [57]

Nevertheless, injectable formulations currently demonstrate more consistent weight and cardiovascular outcome data in high-risk populations

2017;32(9):E10E10

Comparatively other antidiabetic drugs show weight gain as their potential side effect

Use apps like Clue or Flo, or simply note symptoms in a calendar

This is temporary and typically reverses after restarting therapy